COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

A Placebo Controlled 4 Week Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis (RO-2351-001-EM)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00746382
Recruitment Status : Withdrawn (Study withdrawn due to business decisions. No subjects were treated.)
First Posted : September 4, 2008
Last Update Posted : December 1, 2016
Fougera Pharmaceuticals Inc.
Information provided by (Responsible Party):

Brief Summary:
The aim of this proof of concept study is to show the safety and efficacy of 0.5 % dermal roflumilast cream in the treatment of atopic dermatitis in adults. This is a multicenter, randomized, double-blind, placebo-controlled, parallel group study. 2-5 % of the body surface area (BSA) should be covered with a mild form of atopic dermatitis. In a 4-week treatment period 38 mg cream is applied two times daily on 0.5 to 1 % of the BSA. After a screening phase, a washout phase of flexible duration (max 30 days, time depending upon pre-medication), the 28 day treatment phase follows.As roflumilast is a potent antiinflammatory substance, a positive effect on this form of dermal disease is anticipated.

Condition or disease Intervention/treatment Phase
Dermatitis Drug: Roflumilast cream Drug: Placebo cream Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 0 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Official Title: A Proof of Concept Study With 0.5% Roflumilast Cream in Patients With Mild Atopic Dermatitis
Study Start Date : November 2008
Estimated Primary Completion Date : June 2009
Estimated Study Completion Date : September 2009

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Eczema
Drug Information available for: Roflumilast

Arm Intervention/treatment
Active Comparator: 1
Roflumilast cream 0.5%
Drug: Roflumilast cream
Roflumilast cream 0.5% versus Placebo cream

Placebo Comparator: 2
Placebo cream
Drug: Placebo cream
Placebo cream

Primary Outcome Measures :
  1. Improvement of clinical signs and symptoms score, improvement of patient judged pruritus severity [ Time Frame: 28 days ]

Secondary Outcome Measures :
  1. Improvement of atopic dermatitis severity score, change in dermal questionaire, safety and efficacy [ Time Frame: 28 days ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 65 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patient /who is able to read, to write and to fully understand English language) has been informed both verbally and in writing about the objectives of the clinical study, the methods, the anticipated benefits and potential risks and the discomfort to which he/she may be exposed, and has given written consent to participation in the study prior to study start and any study-related procedure.
  • Patients are suffering from mild, stable atopic dermatitis Male or female patient of any ethnic origin, age 18 years or older presenting a minimum of 2% to a maximum of 5% BSA affected by stable mild atopic dermatitis (IgE > 10)proven by a dermatologist.
  • Patients must have at least one target lesion of at least 0.5% BSA.
  • No evidence of oozing or crusting atopic dermatitis
  • No lichenification of diseased lesions
  • No excoriation of diseased lesions
  • Patients must be willing to wash out from current active therapy for at least 14 days to Day 1.
  • Women of childbearing potential must have a negative pregnancy test at the Screening and Baseline Visits and agree to use a highly effective method of birth control. A highly effective of birth control is defined at those which result in a low failure rate (i.e. less than 1% per year) when used consistently and correctly such as implants, injectable, combined oral contraceptives, some IUDs, sexual abstinence or vasectomised partner.

Exclusion Criteria:

  • Patient has spontaneously improving or rapidly deteriorating atopic dermatitis.
  • Patient has a physical condition which, in the Investigator´s opinion, might impair evaluation of atopic dermatitis or which exposes the patient to an unacceptable risk by study participation.
  • Patient had prolonged exposure to natural or artificial sources of ultraviolet radiation within 30 days prior to the initiation of treatment or is intending to have such exposure during the study that is thought by the Investigator likely to modify the patient´s disease.
  • The patient had topical or transdermal treatments, such as but not limited to retinoids, nicotine or hormone replacement therapies, on or near the intended site of application within 14 days prior to first application of study medication. Use of other topical preparations such as those containing vitamins, supplements or herbal within 14 days prior to application.
  • Treatment with systemic/locally acting medications/procedures which might counter or influence the study aim within 30 days before the start and during the study /e.g. anti-histamines, topical glucocorticosteroids, pimecrolimus , tacrolimus systematic desensitization)
  • Patient is pregnant, nursing or planning a pregnancy during the study period.
  • Patient has received an investigational drug or an investigational device within 30 days prior to study start.
  • Abuse of alcohol or drugs

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00746382

Sponsors and Collaborators
Fougera Pharmaceuticals Inc.
Layout table for investigator information
Study Director: AstraZeneca AstraZeneca AstraZeneca
Layout table for additonal information
Responsible Party: AstraZeneca Identifier: NCT00746382    
Other Study ID Numbers: RO-2351-001-EM
First Posted: September 4, 2008    Key Record Dates
Last Update Posted: December 1, 2016
Last Verified: October 2016
Keywords provided by AstraZeneca:
Mild atopic dermatitis, Roflumilast cream 0.5%
Additional relevant MeSH terms:
Layout table for MeSH terms
Dermatitis, Atopic
Skin Diseases
Skin Diseases, Genetic
Genetic Diseases, Inborn
Skin Diseases, Eczematous
Hypersensitivity, Immediate
Immune System Diseases